Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + oxaliplatin ± bevacizumab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CAPOX is a chemotherapy regimen consisting of two drugs: capecitabine, an oral prodrug of 5-fluorouracil, and oxaliplatin, a platinum-based cytotoxic agent. The regimen may be combined with bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A). Capecitabine inhibits DNA synthesis by interfering with thymidylate synthase after conversion to 5-FU in the body. Oxaliplatin forms DNA crosslinks that inhibit DNA replication and transcription. Bevacizumab blocks VEGF-A from binding its receptors on endothelial cells, inhibiting angiogenesis and thereby starving tumors of their blood supply. This combination is primarily used as first-line therapy for metastatic colorectal cancer and has also been studied in other gastrointestinal cancers[1][2][3][4][5].
- Brand names
- Xeloda (capecitabine)Eloxatin (oxaliplatin)Avastin (bevacizumab)
- Other names
- capecitabine + oxaliplatin ± bevacizumabCAPOX ± bevacizumabXELOX ± bevacizumab
02
Targets
TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)Pt-DNA adduct (DNA-oxaliplatin adduct)
Beyond the preview
Go deeper on capecitabine + oxaliplatin ± bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + oxaliplatin ± bevacizumab.